https://www.cancernetwork.com/view/sequencing-adcs-and-managing-ocular-toxicities-in-breast-cancer-populations2026-07-06T20:30:00Z2026-07-06T20:30:00Z https://www.cancernetwork.com/view/choosing-between-imetelstat-and-luspatercept-in-second-line-mds2026-07-06T19:00:00Z2026-07-06T19:00:00Z https://www.cancernetwork.com/view/access-to-care-and-drug-prices-recent-department-health-human-services-guidance2026-07-06T16:00:00Z2026-07-06T16:00:00Z https://www.cancernetwork.com/view/mrd-test-predicts-chemotherapy-survival-benefit-in-colorectal-liver-metastases2026-07-06T14:58:48.039Z2026-07-06T14:58:48.039Z https://www.cancernetwork.com/view/sequencing-celmods-with-bsabs-and-car-t-as-a-sandwich-strategy-in-multiple-myeloma2026-07-06T14:00:00Z2026-07-06T14:00:00Z https://www.cancernetwork.com/view/sequencing-car-t-cell-therapy-and-bispecific-antibodies-in-relapsed-refractory-multiple-myeloma2026-07-06T12:05:00Z2026-07-06T12:05:00Z https://www.cancernetwork.com/view/top-trial-chemo-osimertinib-in-tp53-mutant-egfr-mutated-nsclc2026-06-29T15:35:00.000Z2026-07-06T12:05:00Z https://www.cancernetwork.com/view/toxicity-management-and-quality-of-life2026-07-06T12:05:00Z2026-07-06T12:05:00Z https://www.cancernetwork.com/view/treatment-duration-and-clinical-management-in-newly-diagnosed-multiple-myeloma2026-07-06T12:05:00Z2026-07-06T12:05:00Z https://www.cancernetwork.com/view/clinical-scenario-1-locally-advanced-cscc2026-07-06T12:05:00Z2026-07-06T12:05:00Z https://www.cancernetwork.com/view/practical-implementation-and-communication-strategies-in-breast-cancer2026-07-06T12:05:00Z2026-07-06T12:05:00Z https://www.cancernetwork.com/view/flaura2-osimertinib-plus-chemo-in-egfr-mutant-nsclc2026-06-29T15:35:00.000Z2026-07-06T12:00:00Z https://www.cancernetwork.com/view/monitoring-the-no-evidence-of-disease-patient-and-multidisciplinary-collaboration2026-07-06T12:00:00Z2026-07-06T12:00:00Z https://www.cancernetwork.com/view/efficacy-response-counseling-and-treatment-duration-in-cscc2026-07-06T12:00:00Z2026-07-06T12:00:00Z https://www.cancernetwork.com/view/treatment-selection-following-anti-cd38-exposure-in-relapsed-refractory-multiple-myeloma2026-07-06T12:00:00Z2026-07-06T12:00:00Z https://www.cancernetwork.com/view/how-does-a-death-doula-support-patients-with-cancer2026-07-06T12:00:00Z2026-07-06T12:00:00Z https://www.cancernetwork.com/view/cepheus-trial-and-mrd-outcomes-in-newly-diagnosed-multiple-myeloma2026-07-06T12:00:00Z2026-07-06T12:00:00Z https://www.cancernetwork.com/view/ocular-toxicity-management-and-multidisciplinary-coordination2026-07-06T12:00:00Z2026-07-06T12:00:00Z https://www.cancernetwork.com/view/24-estimated-rate-of-malignancy-in-breast-lesions-after-discordant-pathology-and-imaging2026-07-05T22:30:00Z2026-07-05T22:30:00Z https://www.cancernetwork.com/view/25-evaluating-the-impact-of-in-office-genetic-testing-on-uptake-and-equity-in-breast-cancer-patients2026-07-05T22:00:00Z2026-07-05T22:00:00Z https://www.cancernetwork.com/view/using-ipss-m-to-identify-hidden-high-risk-lower-risk-mds2026-07-05T18:00:00Z2026-07-05T18:00:00Z https://www.cancernetwork.com/view/how-celmods-milder-gi-aes-may-reduce-discontinuation-rates-in-multiple-myeloma2026-07-05T14:00:00Z2026-07-05T14:00:00Z https://www.cancernetwork.com/view/26-a-nomogram-for-predicting-high-axillary-disease-burden-hr-positive-her2-negative-breast-cancer-after-nac2026-07-04T22:30:00Z2026-07-04T22:30:00Z https://www.cancernetwork.com/view/27-transfusion-and-anemia-management-strategies-in-breast-cancer-patients-undergoing-neoadjuvant-chemotherapy2026-07-04T22:00:00Z2026-07-04T22:00:00Z https://www.cancernetwork.com/view/did-asco-2026-deliver-on-its-biggest-pre-meeting-predictions-2026-07-04T18:00:00Z2026-07-04T18:00:00Z https://www.cancernetwork.com/view/why-celmods-pair-synergistically-with-pis-and-cd38-antibodies-in-multiple-myeloma2026-07-04T14:00:00Z2026-07-04T14:00:00Z https://www.cancernetwork.com/view/28-a-cost-utility-analysis-comparing-indocyanine-green-to-methylene-blue-dye-axillary-lymphatic-mapping-slnb2026-07-03T22:30:00Z2026-07-03T22:30:00Z https://www.cancernetwork.com/view/29-a-demonstration-of-opportunity-cost-in-surgical-delays-when-using-needle-localization-versus-molli-localization-in-breast-surgery2026-07-03T22:00:00Z2026-07-03T22:00:00Z https://www.cancernetwork.com/view/long-term-commands-data-reinforce-luspatercept-as-frontline-mds-therapy2026-07-03T20:00:00Z2026-07-03T20:00:00Z https://www.cancernetwork.com/view/elucidating-car-t-cell-candidacy-for-diffuse-large-b-cell-lymphomas2026-07-03T18:00:00Z2026-07-03T18:00:00Z https://www.cancernetwork.com/view/3-things-you-should-know-about-targeted-therapies-for-gliomas2026-07-03T16:00:00Z2026-07-03T16:00:00Z https://www.cancernetwork.com/view/mezigdomide-drives-41-orr-in-triple-class-refractory-multiple-myeloma2026-07-03T14:00:00Z2026-07-03T14:00:00Z https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-clinical-development-and-early-experience-with-talquetamab2026-07-03T12:05:00Z2026-07-03T12:05:00Z https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-expanding-beyond-bcma-with-gprc5d-targeting2026-07-03T12:00:00Z2026-07-03T12:00:00Z https://www.cancernetwork.com/view/30-accuracy-and-operational-efficiency-of-the-molli-marker-compared-to-needle-localization-in-breast-surgery2026-07-02T22:30:00Z2026-07-02T22:30:00Z https://www.cancernetwork.com/view/31-e-strain-elastography-as-an-adjunct-of-breast-ultrasound-impact-on-biopsy-decision-making2026-07-02T22:00:00Z2026-07-02T22:00:00Z https://www.cancernetwork.com/view/individualizing-full-dose-luspatercept-initiation-in-lower-risk-mds2026-07-02T20:00:00Z2026-07-02T20:00:00Z https://www.cancernetwork.com/view/3-things-you-should-know-about-translating-ctdna-into-clinical-decisions-in-breast-cancer2026-07-02T18:00:00Z2026-07-02T18:00:00Z https://www.cancernetwork.com/view/genomic-prostate-score-identifies-biologically-low-risk-disease2026-07-02T16:00:00Z2026-07-02T16:00:00Z https://www.cancernetwork.com/view/the-top-gi-oncology-trials-of-the-year-ranked-by-dr-nicholas-hornstein2026-07-02T14:00:00Z2026-07-02T14:00:00Z https://www.cancernetwork.com/view/understanding-billing-and-coding-in-radiation-oncology-practice2026-07-02T12:00:00Z2026-07-02T12:00:00Z https://www.cancernetwork.com/view/32-primary-breast-neuroendocrine-carcinoma-synchronous-pancreatic-liver-metastases-literature-review2026-07-01T22:30:00Z2026-07-01T22:30:00Z https://www.cancernetwork.com/view/33-pyoderma-gangrenosum-mimicking-post-mastectomy-flap-failure-management-lessons-from-a-contemporary-case-and-literature-review2026-07-01T22:00:00Z2026-07-01T22:00:00Z https://www.cancernetwork.com/view/epcore-fl-1-regimen-shows-value-across-r-r-follicular-lymphoma-subgroups2026-07-01T20:00:00Z2026-07-01T20:00:00Z https://www.cancernetwork.com/view/fda-grants-breakthrough-device-designation-to-merlin-cp-gep-in-early-stage-melanoma2026-07-01T17:00:00Z2026-07-01T17:00:00Z https://www.cancernetwork.com/view/namodenoson-yields-durable-survival-outcomes-in-pretreated-pancreatic-cancer2026-07-01T15:00:07.889Z2026-07-01T15:00:07.889Z https://www.cancernetwork.com/view/zanubrutinib-rituximab-improves-pfs-in-frontline-mantle-cell-lymphoma2026-07-01T14:30:00Z2026-07-01T14:30:00Z https://www.cancernetwork.com/view/how-will-epcore-fl-1-subgroup-data-impact-r-r-follicular-lymphoma-care-2026-07-01T14:00:00Z2026-07-01T14:00:00Z https://www.cancernetwork.com/view/clinical-outcomes-of-acute-pancreatitis-in-patients-with-multiple-myeloma2026-07-01T13:00:00Z2026-07-01T13:00:00Z https://www.cancernetwork.com/view/optimizing-frontline-selection-and-treatment-free-remission-in-cml2026-07-01T12:00:00Z2026-07-01T12:00:00Z https://www.cancernetwork.com/view/impact-of-asciminib-on-treatment-paradigms2026-07-01T12:00:00Z2026-07-01T12:00:00Z https://www.cancernetwork.com/view/35-magus-magnetically-guided-ultrasound-core-needle-biopsy-of-the-sentinel-lymph-nodes-avoidance-of-axillary-surgery-in-patients-unsure-of-de-escalation2026-06-30T22:30:00Z2026-06-30T22:30:00Z https://www.cancernetwork.com/view/fda-oks-regulatory-t-cell-immunotherapy-in-hematologic-malignancies2026-06-30T22:20:12.117Z2026-06-30T22:20:12.117Z https://www.cancernetwork.com/view/36-correlation-between-disseminated-cancer-cells-and-dcisionrt-predictor-score-in-patients-with-ductal-carcinoma-in-situ2026-06-30T22:00:00Z2026-06-30T22:00:00Z https://www.cancernetwork.com/view/primary-malignant-melanoma-of-the-colon-a-rare-and-challenging-diagnosis2026-06-30T21:00:00Z2026-06-30T21:00:00Z https://www.cancernetwork.com/view/illuminating-optimal-car-t-cell-therapies-across-large-b-cell-lymphoma-groups2026-06-30T20:00:00Z2026-06-30T20:00:00Z https://www.cancernetwork.com/view/what-does-the-future-hold-for-thoracic-oncology-and-ai-use-in-cancer-2026-06-30T17:00:00Z2026-06-30T17:00:00Z https://www.cancernetwork.com/view/tumor-lysis-syndrome-and-the-feasibility-of-an-all-oral-regimen2026-06-30T16:55:00Z2026-06-30T16:55:00Z https://www.cancernetwork.com/view/rationale-for-pairing-sonrotoclax-with-zanubrutinib-in-relapsed-or-refractory-cll2026-06-30T16:46:00Z2026-06-30T16:46:00Z https://www.cancernetwork.com/view/the-unmet-needs-driving-new-mechanisms-in-b-cell-malignancies2026-06-30T16:39:48.442Z2026-06-30T16:39:48.442Z https://www.cancernetwork.com/view/looking-to-the-future-and-where-these-agents-may-fit-in-sequencing2026-06-30T16:29:00Z2026-06-30T16:29:00Z https://www.cancernetwork.com/view/efficacy-and-durability-of-catadegbrutinib-in-relapsed-or-refractory-waldenstr-m-macroglobulinemia2026-06-30T16:24:00Z2026-06-30T16:24:00Z https://www.cancernetwork.com/view/how-btk-degradation-differs-from-inhibition2026-06-30T16:19:00Z2026-06-30T16:19:00Z https://www.cancernetwork.com/view/the-unmet-need-driving-new-mechanisms-in-b-cell-malignancies2026-06-30T16:14:39.687Z2026-06-30T16:14:39.687Z https://www.cancernetwork.com/view/epcoritamab-lenalidomide-significantly-improves-pfs-in-r-r-dlbcl2026-06-30T15:00:00Z2026-06-30T15:00:00Z https://www.cancernetwork.com/view/biomarker-interpretation-and-high-risk-disease-definitions-in-cll2026-06-30T12:05:00Z2026-06-30T12:05:00Z https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-cartitude-4-and-the-evolving-role-of-bcma-car-t-cell-therapy2026-06-30T12:05:00Z2026-06-30T12:05:00Z https://www.cancernetwork.com/view/cns-disease-management-and-screening-strategies-in-her2-positive-metastatic-breast-cancer2026-06-30T12:05:00Z2026-06-30T12:05:00Z https://www.cancernetwork.com/view/her2-positive-metastatic-breast-cancer-patient-selection-and-treatment-duration-considerations2026-06-30T12:00:00Z2026-06-30T12:00:00Z https://www.cancernetwork.com/view/purple-reign-vs-thriller-a-duel-of-the-top-frontline-egfr-nsclc-regimens2026-06-30T12:00:00Z2026-06-30T12:00:00Z https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-setting-the-stage-for-bcma-directed-treatment-strategies2026-06-30T12:00:00Z2026-06-30T12:00:00Z https://www.cancernetwork.com/view/overview-of-first-line-cll-treatment-strategies2026-06-30T12:00:00Z2026-06-30T12:00:00Z https://www.cancernetwork.com/view/tip37-evaluating-barriers-to-home-recovery-after-mastectomy-at-a-single-hospital-system2026-06-29T22:30:00Z2026-06-29T22:30:00Z https://www.cancernetwork.com/view/38-postoperative-analgesia-and-investigating-narcotics-in-breast-cancer-patients-protocol-bhwgi-24-01-pain2026-06-29T22:00:00Z2026-06-29T22:00:00Z https://www.cancernetwork.com/view/asco-breakthrough-2026-wrap-up-precision-oncology-ai-and-biomarkers-define-the-future-of-cancer-care2026-06-29T21:00:43.764Z2026-06-29T21:00:43.764Z https://www.cancernetwork.com/view/mariposa-prophylaxis-biomarkers-and-cns-debate2026-06-29T15:35:00.000Z2026-06-29T15:35:00Z https://www.cancernetwork.com/view/teclistamab-induction-shows-feasibility-in-transplant-eligible-myeloma2026-06-29T15:30:00Z2026-06-29T15:30:00Z https://www.cancernetwork.com/view/mariposa-trial-egfr-mutant-lung-cancer-frontline-strategies2026-06-29T15:30:00.000Z2026-06-29T15:30:00Z https://www.cancernetwork.com/view/fda-accepts-rp1-bla-resubmission-for-advanced-melanoma2026-06-29T15:00:39.776Z2026-06-29T15:00:39.776Z https://www.cancernetwork.com/view/tropion-breast02-and-quality-of-life-considerations2026-06-29T12:05:00Z2026-06-29T12:05:00Z https://www.cancernetwork.com/view/clinical-scenario-1-high-risk-adjuvant-setting-in-cscc-treatment2026-06-29T12:05:00Z2026-06-29T12:05:00Z https://www.cancernetwork.com/view/maia-efficacy-and-mrd-outcomes-in-newly-diagnosed-multiple-myeloma2026-06-29T12:05:00Z2026-06-29T12:05:00Z https://www.cancernetwork.com/view/defining-anti-cd38-refractory-disease-in-relapsed-refractory-multiple-myeloma2026-06-29T12:05:00Z2026-06-29T12:05:00Z https://www.cancernetwork.com/view/systemic-treatment-options-for-cscc-and-mechanism-of-action2026-06-29T12:02:00Z2026-06-29T12:02:00Z https://www.cancernetwork.com/view/cscc-disease-progression-and-comorbidity-considerations2026-06-29T12:00:00Z2026-06-29T12:00:00Z https://www.cancernetwork.com/view/evolving-treatment-strategies-in-relapsed-refractory-multiple-myeloma-integrating-bispecific-antibodies-into-earlier-lines-of-care2026-06-29T12:00:00Z2026-06-29T12:00:00Z https://www.cancernetwork.com/view/maia-long-term-outcomes-in-newly-diagnosed-multiple-myeloma2026-06-29T12:00:00Z2026-06-29T12:00:00Z https://www.cancernetwork.com/view/redefining-lymphoma-standards-of-care-top-datasets-from-asco-and-eha-20262026-06-29T12:00:00Z2026-06-29T12:00:00Z https://www.cancernetwork.com/view/real-world-data-and-neoadjuvant-use-in-cscc2026-06-29T12:00:00Z2026-06-29T12:00:00Z https://www.cancernetwork.com/view/ascent-07-and-triple-negative-breast-cancer-advances2026-06-29T12:00:00Z2026-06-29T12:00:00Z https://www.cancernetwork.com/view/39-predictors-of-delay-in-time-from-diagnostic-breast-imaging-to-needle-core-biopsy2026-06-28T22:30:00Z2026-06-28T22:30:00Z https://www.cancernetwork.com/view/40-an-ai-digital-twin-compares-favorably-to-radiologists-for-landmark-identification-and-measurement-in-early-stage-breast-cancer2026-06-28T22:00:00Z2026-06-28T22:00:00Z https://www.cancernetwork.com/view/pirtobrutinib-earns-positive-chmp-opinion-across-all-cll-treatment-lines2026-06-28T16:00:00Z2026-06-28T16:00:00Z https://www.cancernetwork.com/view/41-unexpected-while-expecting-rare-case-of-pregnancy-associated-xanthogranulomatous-mastitis-masquerading-as-malignancy2026-06-27T22:30:00Z2026-06-27T22:30:00Z https://www.cancernetwork.com/view/42-intraoperative-frozen-analysis-of-sentinel-lymph-nodes-after-neoadjuvant-chemotherapy-does-not-provide-additional-surgical-benefit-and-increases-the-rate-of-unnecessary-alnd-in-clinically-node-negative-breast-cancer-patients2026-06-27T22:00:00Z2026-06-27T22:00:00Z https://www.cancernetwork.com/view/wrapping-a-warm-blanket-around-patients-in-a-state-of-the-art-center2026-06-27T14:00:00Z2026-06-27T14:00:00Z https://www.cancernetwork.com/view/ai-and-mrd-take-center-stage-on-day-2-of-asco-breakthrough-20262026-06-27T13:00:00Z2026-06-27T13:00:00Z https://www.cancernetwork.com/view/43-mp2-the-next-generation-marginprobe-device-incremental-performance-gains-in-an-area-of-persistent-unmet-need2026-06-26T22:30:00Z2026-06-26T22:30:00Z https://www.cancernetwork.com/view/44-long-term-oncological-outcomes-after-oncoplastic-therapeutic-mammoplasty-with-contralateral-symmetrisation-for-early-breast-cancer-a-thirteen-year-single-centre-cohort-study2026-06-26T22:00:00Z2026-06-26T22:00:00Z https://www.cancernetwork.com/view/overcoming-pd-1-resistance-in-relapsed-refractory-hodgkin-lymphoma2026-06-26T20:00:00Z2026-06-26T20:00:00Z